Meta-analysis of 5 placebo-controlled RCTs in adolescents and adults with moderate-to-severe plaque psoriasis: oral icotrokinra raised IGA 0/1 at week 16 (RR 7.27, 95% CI 5.80–9.11) and PASI 90 (RR 13.8); adverse event rates were comparable to placebo.
Meta-analysisn = 5 trials
Advani et al. Efficacy and safety of icotrokinra for plaque psoriasis: a systematic review and meta-analysis